secwatch.observer — SEC 8-K summary
======================================

Issuer:     Absci Corp (ABSI)
CIK:        0001672688
Form:       8-K
Filed at:   2026-06-24T20:31:58+00:00
Accession:  0001193125-26-281143
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Absci prices $100M common stock offering at $7.41/share; Lilly, other investors participate
--------------------------------------------------------------------------------

- 13,495,277 shares priced at $7.41 each; gross proceeds ~$100M, net ~$93.5M after fees.
- Offering includes participation from Eli Lilly, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile.
- Net proceeds to fund AI-designed anti-PRLR antibody ABS-201 for alopecia and endometriosis.
- Offering expected to close June 25, 2026; Jefferies, J.P. Morgan, TD Cowen, Guggenheim as bookrunners.
- Shares sold under effective shelf registration statement (File No. 333-289541).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672688/000119312526281143/0001193125-26-281143-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672688/000119312526281143/d139233d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-281143

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer